MMP-9 Recombinant Protein: A Key Driver of Glymphatic System Dysfunction in Parkinson's Disease

Author: Senior Product Manager of UA Views：16

This article focuses on the molecular characteristics and biological functions of matrix metalloproteinase-9 (MMP-9), systematically elaborating its molecular mechanism in the course of Parkinson's disease by cleaving β-dystroglycan, leading to aquaporin-4 depolarization and glymphatic system dysfunction, analyzing the pathological driving role of MMP-9 in neuroinflammation and neurodegeneration, and exploring the clinical significance of inhibiting MMP-9 as a potential target for enhancing glymphatic system function and neuroprotection.

Recent Advances
Product Information

Recent Advances

MMP-9 Recombinant Protein: A Key Driver of Glymphatic System Dysfunction in Parkinson's Disease

Brief Introduction: This article focuses on the molecular characteristics and biological functions of matrix metalloproteinase-9 (MMP-9), systematically elaborating on its molecular mechanism in the course of Parkinson's disease whereby it cleaves β-dystroglycan, leading to aquaporin-4 depolarization and glymphatic system dysfunction, analyzing the pathological driving role of MMP-9 in neuroinflammation and neurodegeneration, and exploring the clinical significance of inhibiting MMP-9 as a potential target for enhancing glymphatic system function and neuroprotection.

I. Disease Characteristics of Parkinson's Disease and Glymphatic System Dysfunction.

Parkinson's disease is the second most common neurodegenerative disease, characterized by degeneration of dopaminergic neurons in the substantia nigra and abnormal aggregation of α-synuclein, leading to the abnormal accumulation of Lewy bodies. The glymphatic system is a paravascular pathway that clears pathological proteins and metabolic products. In Parkinson's disease, glymphatic system dysfunction is associated with disease mechanisms, but its specific molecular mechanism remains unclear. This knowledge gap has driven researchers to deeply explore the molecules that regulate glymphatic system function.

II. Structural Basis of AQP4 Polarization and Glymphatic System Function.

Aquaporin-4 (AQP4) is a channel protein that facilitates high-speed transport of water and solutes, and its localization at astrocyte endfeet, namely AQP4 polarization, is crucial for the effective operation of the glymphatic system. Many lines of evidence have revealed the link between abnormal AQP4 expression and the pathological progression of neurodegenerative diseases. Previous studies have shown that the polarized expression pattern of AQP4 depends on an intact dystroglycan complex. This complex is located on the astrocyte endfoot membrane and consists of an extracellular α subunit and a transmembrane β subunit. The structural integrity of β-DG is crucial for the contact between the basement membrane and the astrocyte membrane and for AQP4 polarization, and the extracellular N-terminus of β-DG is a specific substrate for cleavage by matrix metalloproteinase-9. MMP-9 can be synthesized by neurons and glial cells and released into the extracellular space, disrupting extracellular matrix homeostasis and playing a role in neuroinflammation and neurodegeneration. This structural basis reveals the molecular association among MMP-9, β-DG, and AQP4.

III. Pathological Mechanism by Which MMP-9 Cleaves β-DG Leading to AQP4 Depolarization.

The authors propose a hypothesis: during the course of Parkinson's disease, activated MMP-9 is released and infiltrates the perivascular region, cleaving the extracellular domain of β-DG, leading to structural instability at the contact zone between the basement membrane and astrocyte endfeet, depolarization of AQP4 protein, and consequently glymphatic system dysfunction. Inhibiting MMP-9 can suppress AQP4 depolarization-mediated glymphatic system dysfunction, as well as partially alleviate metabolic disorders and dopaminergic neuronal degeneration.

In experimental validation, glymphatic system function was impaired in MPTP-induced Parkinson's disease mice. Quantitative analysis of influx function showed that compared with the saline group, the tracer fluorescence intensity in the brain of the MPTP group was significantly reduced, especially in the midbrain and substantia nigra. Using the clearance rate of tracers of different molecular weights from the interstitial fluid from the brain to represent efflux function, 2 hours after intrastriatal injection of tracer, the tracer retention in the striatum of the MPTP group was significantly increased. These results confirmed the dual impairment of glymphatic system influx and efflux function in the Parkinson's disease mouse model.

IV. Experimental Evidence of MMP-9-Mediated β-DG Cleavage.

To verify whether MMP-9 cleaves β-DG in Parkinson's disease mouse models, the authors performed validation in A53T Parkinson's disease transgenic mice and MPTP-induced Parkinson's disease mice. In A53T mice, the expression levels of pro-MMP-9 and cleaved β-DG were higher than in wild-type mice; in MPTP-induced Parkinson's disease mice, the expression levels of activated MMP-9 and cleaved β-DG were higher than in the saline-treated group. Treatment with the MMP-9 inhibitor GM6001 significantly reduced the levels of pro-MMP-9 and activated MMP-9 in MPTP-induced Parkinson's disease mice. This indicates that MMP-9 mediates the β-DG cleavage process in Parkinson's disease mouse models. Furthermore, immunofluorescence confirmed that compared with the saline group and the MPTP plus GM6001 group, MMP-9 was increased and β-DG expression was decreased in the MPTP plus vehicle group. Immunofluorescence showed that in the MPTP plus vehicle group, MMP-9 mainly accumulated within neurons and infiltrated the perivascular structures surrounded by astrocyte endfeet. The immunoreactivity of MMP-9 was associated with local loss of β-DG content. This evidence fully establishes the causal relationship among MMP-9 activation, β-DG cleavage, and perivascular structural damage.

V. Restorative Effects of MMP-9 Inhibition on AQP4 Polarity and Neuropathology.

Co-immunoprecipitation showed that AQP4 co-precipitated with β-DG but not with IgG, confirming the physical binding of AQP4 to β-DG. Compared with the MPTP plus vehicle group, after GM6001 treatment, the expression levels of AQP4-M1 and AQP4-M23 were upregulated, and the expression level of the reactive astrocyte marker GFAP was attenuated. In addition, compared with the MPTP plus solvent group, after GM6001 treatment, the number of AQP4-positive and β-DG-positive cells increased, and the number of labeled AQP4- and β-DG-positive cells uniformly recovered along the perivascular region.

Cleaved β-DG, having lost its binding site for extracellular α-DG, leads to sparse distribution of astrocyte endfeet along the perivascular basement membrane. Transmission electron microscopy was used to explore the ultrastructural changes at the basement membrane-astrocyte endfoot contact zone in the substantia nigra. Compared with the saline group, astrocyte endfeet in the MPTP plus solvent group were severely swollen, rounded, and even detached from the basement membrane, and GM6001 restored the contact between the basement membrane and astrocyte endfeet. These findings indicate that increased MMP-9 activity cleaves perivascular β-DG, leading to AQP4 depolarization and sparse distribution of astrocyte endfeet at the basement membrane, and inhibition of MMP-9 can reverse these phenomena. In addition, TH immunofluorescence showed that the number of TH-positive neurons in the substantia nigra partially recovered.

VI. Conclusion.

In MMP-9-related basic research and exploration of neurodegenerative disease mechanisms, high-quality recombinant MMP-9 protein is a core tool for dissecting its substrate cleavage specificity and evaluating inhibitor activity. In response to the needs of MMP-9 function research and Parkinson's disease mechanism exploration, Uni-Ai provides MMP-9 His Tag Protein, Mouse. This product is suitable for applications such as analysis of MMP-9 cleavage activity toward substrates including β-DG, in vitro screening and evaluation of MMP-9 inhibitors, mechanistic research on MMP-9 in neuroinflammation and glymphatic system dysfunction, and development of Parkinson's disease-related therapeutic strategies.

As a key driver of glymphatic system dysfunction in Parkinson's disease, MMP-9, by virtue of its unique molecular mechanism of cleaving the extracellular domain of β-DG to cause structural instability at the basement membrane-astrocyte endfoot contact zone and AQP4 depolarization, has become a core molecular node linking neuroinflammation, perivascular structural damage, and glymphatic system dysfunction. From MMP-9 activation and β-DG cleavage in Parkinson's disease mouse models, to the dual impairment of glymphatic system influx and efflux function caused by AQP4 depolarization, and further to the reversal effects of MMP-9 inhibition on AQP4 polarity recovery and neuroprotection, MMP-9 continues to drive the in-depth development of research on the pathogenesis of Parkinson's disease. MMP-9 His Tag Protein, Mouse provides reliable tool support for mechanistic research on the MMP-9 signaling network and targeted drug development, and will continue to facilitate innovative exploration in the field of neurodegenerative disease therapeutics.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Next